12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Micardis HCT telmisartan/hydrochlorothiazide regulatory update

The FDA granted marketing approval for Micardis HCT, a combination angiotensin II receptor antagonist and...

Read the full 52 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >